. 2016 Oct 13;25(4):747–754. doi: 10.1016/j.sjbs.2016.10.007

Table 1.

Effect of crocin treatment on hepatotoxicity markers in a mouse model of TAA-induced liver fibrosis.

Group	ALT	AST	TB	TC	TG
Group	U/L	U/L	mg/dL	mg/dL	mg/dL
Control	16.02^b ± 4.23	13.25^b ± 2.04	0.23^b ± 0.084	58.98^b ± 3.06	73.13^b ± 3.79
Thioacetamide (TAA; 100 mg/kg)	129.13^a ± 17.09	95.54^a ± 3.53	1.20^a ± 0.249	126.53^a ± 6.56	156.90^a ± 8.14
TAA + crocin 25 mg/kg	52.86^a^,^b ± 0.43	47.28^a^,^b ± 3.22	0.83^a^,^b ± 0.29	124.00^a ± 6.43	153.76^a ± 7.97
TAA + crocin 100 mg/kg	28.00^a^,^b ± 0.50	29.14^a^,^b ± 5.18	0.36^a^,^b ± 0.129	69.45^a^,^b ± 3.60	86.12^a^,^b ± 4.46
TAA + silymarin100 mg/kg	22.17^b ± 5.24	19.46^b ± 4.32	0.29^b ± 0.103	64.29^b ± 3.33	79.71^b ± 4.13

n = 6.

Statistical analysis was carried out by a one-way ANOVA followed by Tukey’s post hoc test.

Statistically significant from the corresponding control at p < 0.05.

Statistically significant from TAA-treated group at p < 0.05.